320 related articles for article (PubMed ID: 25205430)
21. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
22. Is the improved prognosis of p16 positive oropharyngeal squamous cell carcinoma dependent of the treatment modality?
Fischer CA; Zlobec I; Green E; Probst S; Storck C; Lugli A; Tornillo L; Wolfensberger M; Terracciano LM
Int J Cancer; 2010 Mar; 126(5):1256-62. PubMed ID: 19697324
[TBL] [Abstract][Full Text] [Related]
23. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
[TBL] [Abstract][Full Text] [Related]
24. Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma.
Geiger JL; Lazim AF; Walsh FJ; Foote RL; Moore EJ; Okuno SH; Olsen KD; Kasperbauer JL; Price DL; Garces YI; Ma DJ; Neben-Wittich MA; Molina JR; Garcia JJ; Price KA
Oral Oncol; 2014 Apr; 50(4):311-8. PubMed ID: 24467937
[TBL] [Abstract][Full Text] [Related]
25. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation.
Kim SH; Koo BS; Kang S; Park K; Kim H; Lee KR; Lee MJ; Kim JM; Choi EC; Cho NH
Int J Cancer; 2007 Apr; 120(7):1418-25. PubMed ID: 17205528
[TBL] [Abstract][Full Text] [Related]
26. Small molecule-based chemotherapeutic approach in p16-positive and -negative HNSCC in vitro.
Aderhold C; Faber A; Grobschmidt GM; Chakraborty A; Bockmayer A; Umbreit C; Birk R; Stern-Straeter J; Hörmann K; Schultz JD
Anticancer Res; 2013 Dec; 33(12):5385-93. PubMed ID: 24324073
[TBL] [Abstract][Full Text] [Related]
27. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
Leng AM; Liu T; Yang J; Cui JF; Li XH; Zhu YN; Xiong T; Zhang G; Chen Y
Cell Biol Int; 2012 Oct; 36(10):893-9. PubMed ID: 22694478
[TBL] [Abstract][Full Text] [Related]
28. Impact of Expression of CD44, a Cancer Stem Cell Marker, on the Treatment Outcomes of Intensity Modulated Radiation Therapy in Patients With Oropharyngeal Squamous Cell Carcinoma.
Motegi A; Fujii S; Zenda S; Arahira S; Tahara M; Hayashi R; Akimoto T
Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):461-8. PubMed ID: 26867875
[TBL] [Abstract][Full Text] [Related]
29. HPV status and overall survival of patients with oropharyngeal squamous cell carcinoma--a retrospective study of a German head and neck cancer center.
Tahtali A; Hey C; Geissler C; Filman N; Diensthuber M; Leinung M; Stöver T; Wagenblast J
Anticancer Res; 2013 Aug; 33(8):3481-5. PubMed ID: 23898123
[TBL] [Abstract][Full Text] [Related]
30. Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma.
Young RJ; Rischin D; Fisher R; McArthur GA; Fox SB; Peters LJ; Corry J; Lim A; Waldeck K; Solomon B
Cancer Epidemiol Biomarkers Prev; 2011 Jun; 20(6):1230-7. PubMed ID: 21467228
[TBL] [Abstract][Full Text] [Related]
31. Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation.
Machida H; Matsumoto Y; Shirai M; Kubota N
Int J Radiat Biol; 2003 Dec; 79(12):973-80. PubMed ID: 14713575
[TBL] [Abstract][Full Text] [Related]
32. Expression of p16, Rb, and p53 proteins in squamous cell carcinomas of the anorectal region harboring human papillomavirus DNA.
Lu DW; El-Mofty SK; Wang HL
Mod Pathol; 2003 Jul; 16(7):692-9. PubMed ID: 12861066
[TBL] [Abstract][Full Text] [Related]
33. Metachronous squamous cell carcinomas evolving from independent oropharyngeal and pulmonary squamous papillomas: association with human papillomavirus 11 and lack of aberrant p53, Rb, and p16 protein expression.
Xu H; Lu DW; El-Mofty SK; Wang HL
Hum Pathol; 2004 Nov; 35(11):1419-22. PubMed ID: 15668901
[TBL] [Abstract][Full Text] [Related]
34. Imatinib-associated matrix metalloproteinase suppression in p16-positive squamous cell carcinoma compared to HPV-negative HNSCC cells in vitro.
Umbreit C; Aderhold C; Faber A; Sauter A; Hofheinz RD; Stern-Straeter J; Hoermann K; Schultz JD
Oncol Rep; 2014 Aug; 32(2):668-76. PubMed ID: 24890748
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
36. Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.
Nagaraju GP; Park W; Wen J; Mahaseth H; Landry J; Farris AB; Willingham F; Sullivan PS; Proia DA; El-Hariry I; Taliaferro-Smith L; Diaz R; El-Rayes BF
Angiogenesis; 2013 Oct; 16(4):903-17. PubMed ID: 23838996
[TBL] [Abstract][Full Text] [Related]
37. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma.
Licitra L; Perrone F; Bossi P; Suardi S; Mariani L; Artusi R; Oggionni M; Rossini C; Cantù G; Squadrelli M; Quattrone P; Locati LD; Bergamini C; Olmi P; Pierotti MA; Pilotti S
J Clin Oncol; 2006 Dec; 24(36):5630-6. PubMed ID: 17179101
[TBL] [Abstract][Full Text] [Related]
38. Assessing for primary oropharyngeal or nasopharyngeal squamous cell carcinoma from fine needle aspiration of cervical lymph node metastases.
Jannapureddy S; Cohen C; Lau S; Beitler JJ; Siddiqui MT
Diagn Cytopathol; 2010 Nov; 38(11):795-800. PubMed ID: 20014308
[TBL] [Abstract][Full Text] [Related]
39. Hsp90 Inhibitor Ganetespib Sensitizes Non-Small Cell Lung Cancer to Radiation but Has Variable Effects with Chemoradiation.
Wang Y; Liu H; Diao L; Potter A; Zhang J; Qiao Y; Wang J; Proia DA; Tailor R; Komaki R; Lin SH
Clin Cancer Res; 2016 Dec; 22(23):5876-5886. PubMed ID: 27354472
[TBL] [Abstract][Full Text] [Related]
40. Efficacy of an HSP90 inhibitor, ganetespib, in preclinical thyroid cancer models.
Lin SF; Lin JD; Hsueh C; Chou TC; Yeh CN; Chen MH; Wong RJ
Oncotarget; 2017 Jun; 8(25):41294-41304. PubMed ID: 28476040
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
